Search research articles

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 Trial.

JCO oncology advances·2026

Same author

Clonal Hematopoiesis of Indeterminate Potential After Radiation Therapy.

International journal of radiation oncology, biology, physics·2025

Same author

Distinct and convergent effects of <i>SF3B1</i> mutations in human breast cancer.

Proceedings of the National Academy of Sciences of the United States of America·2025

Same author

Identification of asporin as a HER3 ligand exposes a therapeutic vulnerability in prostate cancer.

JCI insight·2025

Same author

Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in Prostate Cancer Patients of the All of Us Research Program Cohort.

The Prostate·2025

Same author

Prevalence and Associated Factors for Depression Among Patients With Sarcoma.

JCO oncology practice·2025

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Sep 8, 2025

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Circulating tumor DNA: current challenges for clinical utility.

Donna K Dang, Ben H Park

The Journal of Clinical Investigation

|June 15, 2022

Summary

Circulating tumor DNA (ctDNA) from liquid biopsies offers a noninvasive way to track cancer mutations. Research explores ctDNA for guiding treatment, detecting minimal residual disease, and early cancer screening.

Area of Science:

Oncology
Molecular Biology
Genetics

Background:

Circulating tumor DNA (ctDNA) is shed by cancer cells into the bloodstream.
ctDNA analysis via liquid biopsies provides insights into the cancer's mutational landscape.
ctDNA is increasingly used in precision medicine for mutation detection and companion diagnostics.

Purpose of the Study:

To review the history and evolution of ctDNA and liquid biopsy technologies.
To discuss current applications of ctDNA in guiding cancer treatment decisions.
To evaluate the potential and challenges of ctDNA for minimal residual disease detection and cancer screening.

Main Methods:

Review of existing literature on ctDNA and liquid biopsy technologies.
Analysis of ctDNA's role in next-generation sequencing for mutation detection.

More Related Videos

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

Target Cell Pre-enrichment and Whole Genome Amplification for Single Cell Downstream Characterization

Target Cell Pre-enrichment and Whole Genome Amplification for Single Cell Downstream Characterization

Published on: May 15, 2018

Related Experiment Videos

Last Updated: Sep 8, 2025

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

Target Cell Pre-enrichment and Whole Genome Amplification for Single Cell Downstream Characterization

Target Cell Pre-enrichment and Whole Genome Amplification for Single Cell Downstream Characterization

Published on: May 15, 2018

Discussion of clinical applications in targeted therapies and immunotherapies.

Main Results:

ctDNA serves as a noninvasive alternative to tissue biopsies for repeated assessments.
ctDNA guides treatment by predicting response and resistance to therapies.
Emerging research investigates ctDNA for minimal residual disease detection and population-wide cancer screening.

Conclusions:

ctDNA analysis is a rapidly advancing field in oncology with significant clinical potential.
Further rigorous clinical studies are needed to validate ctDNA's utility in minimal residual disease monitoring and cancer screening.
The noninvasive nature of ctDNA liquid biopsies facilitates serial monitoring and personalized cancer management.